Clarivate Plc Key Executives
This section highlights Clarivate Plc's key executives, including their titles and compensation details.
Find Contacts at Clarivate Plc
(Showing 0 of )
Clarivate Plc Earnings
This section highlights Clarivate Plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-19 | $0.20 | $0.21 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $0.19 | $0.19 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $0.18 | $0.20 |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $0.14 | $0.14 |
| Read Transcript | Q4 | 2023 | 2024-03-01 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $0.18 | $0.21 |
| Read Transcript | Q2 | 2023 | 2023-08-06 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-14 | N/A | N/A |
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.
$4.09
Stock Price
$2.82B
Market Cap
12.00K
Employees
London, None
Location
Financial Statements
Access annual & quarterly financial statements for Clarivate Plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.56B | $2.63B | $2.66B | $2.66B | $1.88B |
| Cost of Revenue | $869.20M | $906.40M | $954.00M | $954.00M | $626.10M |
| Gross Profit | $1.69B | $1.72B | $1.71B | $1.71B | $1.25B |
| Gross Profit Ratio | 66.00% | 65.50% | 64.13% | 64.10% | 66.64% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $553.76M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $89.23M |
| Selling General and Administrative Expenses | $727.60M | $739.70M | $729.90M | $729.90M | $642.99M |
| Other Expenses | $1.24B | $1.72B | $4.90B | $385.70M | $565.32M |
| Operating Expenses | $1.96B | $2.46B | $1.12B | $1.12B | $1.21B |
| Cost and Expenses | $2.83B | $3.36B | $2.07B | $2.07B | $1.83B |
| Interest Income | $- | $- | $270.30M | $252.50M | $111.90M |
| Interest Expense | $283.40M | $293.70M | $270.30M | $270.30M | $252.49M |
| Depreciation and Amortization | $727.00M | $708.30M | $710.50M | $537.82M | $303.15M |
| EBITDA | $456.60M | $-10.50M | $-3.01B | $532.15M | $52.38M |
| EBITDA Ratio | 17.86% | -0.40% | 48.90% | 48.90% | 30.92% |
| Operating Income | $-275.60M | $-734.70M | $-3.93B | $590.20M | $42.48M |
| Operating Income Ratio | -10.78% | -27.95% | -147.59% | 22.19% | 2.26% |
| Total Other Income Expenses Net | $-278.20M | $-277.80M | $-63.50M | $-171.15M | $-277.87M |
| Income Before Tax | $-553.80M | $-1.01B | $-3.99B | $-3.99B | $-258.15M |
| Income Before Tax Ratio | -21.66% | -38.52% | -149.98% | -149.98% | -13.75% |
| Income Tax Expense | $82.90M | $-101.30M | $-28.90M | $-28.90M | $12.30M |
| Net Income | $-668.00M | $-911.20M | $-3.96B | $-3.96B | $-270.45M |
| Net Income Ratio | -26.13% | -34.66% | -148.89% | -148.89% | -14.41% |
| EPS | $-0.96 | $-1.47 | $-5.86 | $-6.28 | $-0.63 |
| EPS Diluted | $-0.96 | $-1.47 | $-5.84 | $-6.18 | $-0.63 |
| Weighted Average Shares Outstanding | 693.60M | 671.60M | 676.10M | 630.98M | 428.60M |
| Weighted Average Shares Outstanding Diluted | 693.60M | 671.60M | 678.60M | 640.77M | 428.60M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $663.00M | $622.20M | $650.30M | $621.20M | $683.70M | $647.20M | $668.80M | $629.10M | $668.80M | $629.10M | $686.60M | $662.20M | $560.70M | $442.12M | $445.64M | $428.43M | $455.60M | $284.36M | $273.50M | $240.59M |
| Cost of Revenue | $227.70M | $210.10M | $398.00M | $217.80M | $412.40M | $220.60M | $224.20M | $229.70M | $224.20M | $229.70M | $244.10M | $249.20M | $187.79M | $141.11M | $136.61M | $138.74M | $130.51M | $91.81M | $90.86M | $82.40M |
| Gross Profit | $435.30M | $412.10M | $252.30M | $403.40M | $271.30M | $426.60M | $444.60M | $399.40M | $444.60M | $399.40M | $442.50M | $413.00M | $372.91M | $301.01M | $309.04M | $289.69M | $325.09M | $192.56M | $182.64M | $158.19M |
| Gross Profit Ratio | 65.66% | 66.20% | 38.80% | 64.90% | 39.70% | 65.90% | 66.50% | 63.50% | 66.50% | 63.50% | 64.40% | 62.40% | 66.50% | 68.10% | 69.30% | 67.60% | 71.35% | 67.72% | 66.78% | 65.75% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $185.51M | $98.11M | $95.34M | $104.42M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $180.80M | $169.70M | $185.20M | $191.90M | $180.40M | $171.90M | $192.90M | $194.80M | $192.90M | $194.80M | $186.10M | $193.70M | $184.14M | $141.22M | $149.81M | $111.34M | $185.51M | $98.11M | $95.34M | $104.42M |
| Other Expenses | $316.80M | $220.70M | $491.50M | $206.50M | $1.06B | $167.50M | $- | $150.00M | $340.00M | $140.60M | $170.20M | $183.10M | $176.38M | $135.52M | $129.44M | $147.88M | $137.16M | $68.75M | $47.36M | $45.41M |
| Operating Expenses | $497.60M | $390.40M | $185.20M | $372.90M | $180.40M | $352.70M | $385.50M | $335.40M | $385.50M | $335.40M | $360.60M | $376.80M | $337.21M | $276.74M | $279.26M | $259.23M | $274.75M | $166.87M | $142.70M | $149.83M |
| Cost and Expenses | $725.30M | $600.50M | $583.20M | $590.70M | $592.80M | $573.30M | $609.70M | $565.10M | $609.70M | $565.10M | $604.70M | $626.00M | $525.00M | $417.85M | $415.87M | $397.97M | $405.26M | $258.67M | $233.56M | $232.22M |
| Interest Income | $- | $- | $- | $- | $- | $71.90M | $73.00M | $73.60M | $77.00M | $71.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $69.90M | $72.20M | $71.10M | $70.20M | $75.20M | $71.90M | $73.00M | $73.60M | $73.00M | $73.60M | $62.30M | $59.50M | $111.33M | $65.19M | $38.57M | $37.39M | $39.61M | $20.24M | $21.12M | $30.94M |
| Depreciation and Amortization | $186.00M | $177.20M | $184.40M | $179.40M | $180.80M | $176.80M | $178.10M | $172.60M | $188.80M | $169.70M | $175.60M | $176.40M | $145.30M | $130.68M | $130.18M | $131.65M | $126.95M | $68.61M | $56.15M | $51.44M |
| EBITDA | $123.70M | $198.90M | $-68.10M | $214.30M | $-605.90M | $250.70M | $92.70M | $209.50M | $267.60M | $-4.15B | $257.50M | $212.60M | $145.34M | $228.70M | $8.78M | $113.36M | $109.25M | $-12.66M | $78.17M | $-28.31M |
| EBITDA Ratio | 18.66% | 31.97% | 38.67% | 33.79% | 39.74% | 38.74% | 35.47% | 37.61% | 35.47% | 37.61% | 37.50% | 32.11% | 32.28% | 35.05% | 35.89% | 37.84% | 38.91% | 33.16% | 35.13% | 24.86% |
| Operating Income | $-62.30M | $21.70M | $67.10M | $5.00M | $90.90M | $87.20M | $-88.30M | $54.60M | $-88.30M | $54.60M | $86.20M | $44.90M | $31.93M | $9.07M | $-11.75M | $-34.21M | $29.53M | $-12.66M | $14.25M | $-28.31M |
| Operating Income Ratio | -9.40% | 3.49% | 10.32% | 0.80% | 13.30% | 13.47% | -13.20% | 8.68% | -13.20% | 8.68% | 12.55% | 6.78% | 5.69% | 2.05% | -2.64% | -7.98% | 6.48% | -4.45% | 5.21% | -11.77% |
| Total Other Income Expenses Net | $-69.90M | $-72.20M | $-71.10M | $-65.00M | $-73.70M | $-59.30M | $-70.10M | $-74.70M | $-72.90M | $-18.20M | $-13.30M | $40.90M | $-61.20M | $12.49M | $-7.54M | $-21.49M | $-89.18M | $-20.24M | $-21.12M | $-30.94M |
| Income Before Tax | $-132.20M | $-50.50M | $-311.10M | $-60.00M | $-861.90M | $27.90M | $-158.40M | $-20.10M | $-158.40M | $-20.10M | $72.90M | $85.80M | $-111.30M | $26.89M | $-71.34M | $-20.39M | $-10.08M | $-32.91M | $-6.88M | $-59.25M |
| Income Before Tax Ratio | -19.94% | -8.12% | -47.84% | -9.66% | -126.06% | 4.31% | -23.68% | -3.20% | -23.68% | -3.20% | 10.62% | 12.96% | -19.85% | 6.08% | -16.01% | -4.76% | -2.21% | -11.57% | -2.51% | -24.63% |
| Income Tax Expense | $59.60M | $15.10M | $-6.80M | $15.00M | $-18.00M | $15.60M | $-35.30M | $-63.60M | $-35.30M | $-63.60M | $10.50M | $16.30M | $58.00K | $3.58M | $10.87M | $3.57M | $-16.49M | $4.33M | $-5.38M | $14.75M |
| Net Income | $-191.80M | $-65.60M | $-304.30M | $-75.00M | $-843.90M | $12.30M | $-123.10M | $43.50M | $-123.10M | $43.50M | $43.70M | $69.50M | $-111.35M | $23.31M | $-82.21M | $-23.95M | $6.42M | $-37.23M | $-1.49M | $-74.00M |
| Net Income Ratio | -28.93% | -10.54% | -46.79% | -12.07% | -123.43% | 1.90% | -18.41% | 6.91% | -18.41% | 6.91% | 6.36% | 10.50% | -19.86% | 5.27% | -18.45% | -5.59% | 1.41% | -13.09% | -0.55% | -30.76% |
| EPS | $-0.27 | $-0.09 | $-0.44 | $-0.11 | $-1.27 | $-0.01 | $-0.18 | $0.04 | $-0.18 | $0.06 | $0.06 | $0.10 | $-0.17 | $0.04 | $-0.14 | $-0.04 | $0.01 | $-0.10 | $0.00 | $-0.22 |
| EPS Diluted | $-0.27 | $-0.09 | $-0.44 | $-0.11 | $-1.27 | $-0.01 | $-0.18 | $0.04 | $-0.17 | $0.06 | $0.06 | $0.10 | $-0.17 | $0.04 | $-0.13 | $-0.04 | $0.01 | $-0.10 | $0.00 | $-0.22 |
| Weighted Average Shares Outstanding | 702.80M | 718.70M | 685.60M | 666.90M | 665.00M | 670.90M | 675.90M | 674.80M | 674.20M | 673.60M | 674.30M | 682.50M | 654.89M | 634.51M | 597.73M | 602.27M | 579.65M | 387.20M | 375.88M | 343.13M |
| Weighted Average Shares Outstanding Diluted | 702.80M | 718.70M | 685.60M | 666.90M | 665.00M | 670.90M | 675.90M | 679.30M | 731.00M | 679.30M | 678.40M | 687.99M | 654.89M | 643.90M | 611.09M | 612.60M | 606.09M | 387.85M | 375.88M | 343.13M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $295.20M | $370.70M | $348.80M | $348.80M | $430.88M |
| Short Term Investments | $- | $- | $2.30M | $- | $- |
| Cash and Short Term Investments | $295.20M | $370.70M | $348.80M | $348.80M | $430.88M |
| Net Receivables | $798.30M | $908.30M | $872.10M | $906.40M | $737.73M |
| Inventory | $- | $- | $97.40M | $97.40M | $233.28M |
| Other Current Assets | $151.10M | $183.20M | $166.30M | $299.90M | $152.10M |
| Total Current Assets | $1.24B | $1.46B | $1.40B | $1.40B | $1.64B |
| Property Plant Equipment Net | $107.10M | $106.80M | $113.40M | $113.40M | $169.88M |
| Goodwill | $1.57B | $2.02B | $2.88B | $2.88B | $7.90B |
| Intangible Assets | $8.44B | $9.01B | $9.44B | $9.44B | $10.39B |
| Goodwill and Intangible Assets | $10.01B | $11.03B | $12.31B | $12.31B | $18.30B |
| Long Term Investments | $- | $17.70M | $47.20M | $1.96M | $- |
| Tax Assets | $48.50M | $46.70M | $24.20M | $24.20M | $27.94M |
| Other Non-Current Assets | $82.20M | $43.10M | $50.70M | $95.94M | $50.71M |
| Total Non-Current Assets | $10.25B | $11.24B | $12.55B | $12.55B | $18.55B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $11.49B | $12.71B | $13.94B | $13.94B | $20.18B |
| Account Payables | $124.50M | $144.10M | $101.40M | $129.20M | $82.04M |
| Short Term Debt | $20.60M | $48.80M | $52.40M | $62.80M | $64.06M |
| Tax Payables | $- | $- | $- | $28.54M | $28.54M |
| Deferred Revenue | $859.10M | $983.10M | $947.50M | $947.50M | $1.03B |
| Other Current Liabilities | $429.30M | $424.00M | $458.50M | $1.34B | $1.02B |
| Total Current Liabilities | $1.43B | $1.60B | $1.56B | $1.56B | $1.90B |
| Long Term Debt | $4.57B | $4.78B | $5.05B | $5.55B | $3.56B |
| Deferred Revenue Non-Current | $- | $38.70M | $38.50M | $38.50M | $54.25M |
| Deferred Tax Liabilities Non-Current | $273.30M | $249.60M | $316.10M | $316.10M | $380.06M |
| Other Non-Current Liabilities | $72.50M | $41.90M | $171.40M | $22.30M | $2.38B |
| Total Non-Current Liabilities | $4.92B | $5.11B | $5.57B | $5.57B | $6.36B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $6.35B | $6.71B | $7.13B | $7.13B | $8.26B |
| Preferred Stock | $- | $1.39B | $1.39B | $1.39B | $1.39B |
| Common Stock | $12.98B | $11.74B | $11.74B | $11.74B | $11.83B |
| Retained Earnings | $-7.31B | $-6.65B | $-5.66B | $-5.66B | $-1.60B |
| Accumulated Other Comprehensive Income Loss | $-526.30M | $-495.30M | $-665.90M | $-665.90M | $326.75M |
| Other Total Stockholders Equity | $- | $- | $- | $-5.13B | $2.70B |
| Total Stockholders Equity | $5.14B | $5.99B | $6.81B | $6.81B | $11.93B |
| Total Equity | $5.14B | $5.99B | $6.81B | $6.81B | $11.93B |
| Total Liabilities and Stockholders Equity | $11.49B | $12.71B | $13.94B | $13.94B | $20.18B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $11.49B | $12.71B | $13.94B | $13.94B | $20.18B |
| Total Investments | $- | $17.70M | $47.20M | $1.96M | $- |
| Total Debt | $4.59B | $4.81B | $5.10B | $5.10B | $5.61B |
| Net Debt | $4.30B | $4.44B | $4.76B | $4.76B | $5.18B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $295.20M | $388.50M | $376.40M | $361.80M | $370.70M | $398.90M | $436.10M | $364.20M | $436.10M | $364.20M | $359.70M | $500.20M | $430.88M | $2.48B | $2.56B | $399.01M | $257.73M | $601.08M | $608.52M | $308.02M |
| Short Term Investments | $- | $- | $- | $- | $4.10M | $8.40M | $- | $- | $2.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $295.20M | $388.50M | $376.40M | $361.80M | $370.70M | $398.90M | $436.10M | $364.20M | $436.10M | $364.20M | $359.70M | $500.20M | $430.88M | $2.48B | $2.56B | $399.01M | $257.73M | $601.08M | $608.52M | $308.02M |
| Net Receivables | $798.30M | $771.80M | $796.30M | $822.90M | $908.30M | $766.90M | $769.70M | $838.60M | $872.10M | $748.60M | $812.40M | $859.80M | $906.43M | $610.75M | $628.13M | $706.88M | $737.73M | $238.64M | $279.16M | $343.18M |
| Inventory | $- | $- | $- | $138.20M | $-4.10M | $133.80M | $135.00M | $121.50M | $135.00M | $121.50M | $115.30M | $113.20M | $233.28M | $1.91B | $2.08B | $77.91M | $70.05M | $85.87M | $53.45M | $54.95M |
| Other Current Assets | $151.10M | $178.80M | $249.20M | $206.10M | $183.20M | $208.90M | $211.80M | $248.50M | $164.00M | $257.20M | $188.10M | $190.10M | $143.20M | $2.10B | $2.30B | $308.12M | $152.10M | $104.54M | $72.41M | $77.05M |
| Total Current Assets | $1.24B | $1.34B | $1.33B | $1.39B | $1.46B | $1.37B | $1.42B | $1.45B | $1.42B | $1.45B | $1.36B | $1.55B | $1.64B | $5.19B | $5.49B | $1.41B | $1.33B | $944.25M | $960.09M | $728.25M |
| Property Plant Equipment Net | $107.10M | $105.40M | $94.20M | $101.20M | $106.80M | $106.60M | $103.60M | $111.20M | $103.60M | $111.20M | $145.40M | $160.60M | $169.88M | $73.83M | $82.77M | $117.62M | $168.62M | $123.53M | $124.95M | $126.95M |
| Goodwill | $1.57B | $1.74B | $1.74B | $2.02B | $2.02B | $2.87B | $2.90B | $2.89B | $2.90B | $2.89B | $7.53B | $7.80B | $7.90B | $6.20B | $6.32B | $6.25B | $6.25B | $1.82B | $1.82B | $1.82B |
| Intangible Assets | $8.44B | $8.73B | $8.77B | $8.87B | $9.01B | $8.96B | $9.19B | $9.40B | $9.19B | $9.40B | $9.70B | $10.14B | $10.39B | $6.96B | $7.20B | $7.27B | $7.37B | $2.22B | $2.26B | $2.28B |
| Goodwill and Intangible Assets | $10.01B | $10.46B | $10.51B | $10.90B | $11.03B | $11.82B | $12.08B | $12.29B | $12.08B | $12.29B | $17.23B | $17.94B | $18.30B | $13.16B | $13.51B | $13.51B | $13.62B | $4.04B | $4.09B | $4.11B |
| Long Term Investments | $- | $7.40M | $26.00M | $25.70M | $17.70M | $2.50M | $31.00M | $18.50M | $47.20M | $50.40M | $- | $- | $1.96M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $48.50M | $50.80M | $49.30M | $46.60M | $46.70M | $26.40M | $26.50M | $24.70M | $26.50M | $24.70M | $28.20M | $28.60M | $27.94M | $30.11M | $27.52M | $27.35M | $29.79M | $25.52M | $17.16M | $15.65M |
| Other Non-Current Assets | $82.20M | $64.40M | $65.60M | $42.80M | $43.10M | $87.30M | $45.00M | $45.40M | $28.80M | $13.50M | $71.30M | $63.10M | $48.75M | $41.81M | $42.15M | $42.50M | $47.94M | $21.84M | $22.18M | $22.82M |
| Total Non-Current Assets | $10.25B | $10.69B | $10.74B | $11.11B | $11.24B | $12.04B | $12.29B | $12.49B | $12.29B | $12.49B | $17.48B | $18.19B | $18.55B | $13.31B | $13.67B | $13.70B | $13.87B | $4.21B | $4.25B | $4.27B |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $11.49B | $12.03B | $12.08B | $12.50B | $12.71B | $13.42B | $13.71B | $13.94B | $13.71B | $13.94B | $18.84B | $19.74B | $20.18B | $18.50B | $19.15B | $15.11B | $15.20B | $5.15B | $5.21B | $5.00B |
| Account Payables | $124.50M | $126.50M | $128.10M | $102.70M | $144.10M | $99.20M | $108.20M | $101.70M | $101.40M | $105.90M | $116.70M | $117.30M | $129.20M | $94.49M | $86.97M | $94.55M | $82.04M | $19.90M | $22.07M | $28.58M |
| Short Term Debt | $20.60M | $22.10M | $69.40M | $47.00M | $48.80M | $48.10M | $25.30M | $50.30M | $25.70M | $86.30M | $116.90M | $91.60M | $94.95M | $1.92B | $2.09B | $96.39M | $99.51M | $63.98M | $60.73M | $63.35M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $39.50M | $35.80M | $28.54M | $37.05M | $35.91M | $42.87M | $45.12M | $- | $- | $- |
| Deferred Revenue | $859.10M | $890.20M | $912.40M | $1.01B | $983.10M | $889.20M | $939.60M | $1.04B | $939.60M | $1.04B | $956.70M | $1.08B | $1.03B | $579.93M | $664.90M | $769.03M | $707.32M | $326.10M | $424.19M | $472.10M |
| Other Current Liabilities | $429.30M | $486.80M | $375.20M | $455.00M | $424.00M | $432.10M | $424.80M | $417.60M | $1.43B | $582.50M | $431.70M | $465.70M | $618.88M | $527.21M | $546.21M | $464.58M | $635.78M | $252.70M | $204.41M | $214.29M |
| Total Current Liabilities | $1.43B | $1.53B | $1.49B | $1.61B | $1.60B | $1.47B | $1.50B | $1.61B | $1.50B | $1.61B | $1.66B | $1.79B | $1.90B | $3.16B | $3.42B | $1.47B | $1.57B | $662.68M | $711.40M | $778.32M |
| Long Term Debt | $4.57B | $4.69B | $4.69B | $4.73B | $4.78B | $4.90B | $4.96B | $4.93B | $5.11B | $5.49B | $5.47B | $5.51B | $5.55B | $3.50B | $3.51B | $3.53B | $3.56B | $1.99B | $1.99B | $2.00B |
| Deferred Revenue Non-Current | $- | $21.60M | $23.90M | $17.70M | $38.70M | $36.50M | $37.90M | $38.00M | $37.90M | $38.00M | $50.30M | $54.70M | $54.25M | $44.93M | $48.14M | $45.40M | $41.40M | $24.08M | $19.12M | $18.77M |
| Deferred Tax Liabilities Non-Current | $273.30M | $227.00M | $229.00M | $246.20M | $249.60M | $255.60M | $262.10M | $313.60M | $262.10M | $313.60M | $366.00M | $376.70M | $380.06M | $324.96M | $338.66M | $351.94M | $362.26M | $95.53M | $86.25M | $94.64M |
| Other Non-Current Liabilities | $72.50M | $52.50M | $49.90M | $11.70M | $41.90M | $71.80M | $10.60M | $93.20M | $108.80M | $161.20M | $244.90M | $300.90M | $370.59M | $254.28M | $341.11M | $320.09M | $67.72M | $19.99M | $16.96M | $18.55M |
| Total Non-Current Liabilities | $4.92B | $4.99B | $4.99B | $5.00B | $5.11B | $5.27B | $5.27B | $5.37B | $5.27B | $5.37B | $6.13B | $6.24B | $6.36B | $4.13B | $4.24B | $4.25B | $4.03B | $2.13B | $2.12B | $2.13B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $6.35B | $6.52B | $6.47B | $6.62B | $6.71B | $6.74B | $6.77B | $6.98B | $6.77B | $6.98B | $7.80B | $8.03B | $8.26B | $7.29B | $7.66B | $5.72B | $5.60B | $2.79B | $2.83B | $2.91B |
| Preferred Stock | $- | $- | $- | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $1.39B | $- | $196.04M | $1 | $1 | $1 |
| Common Stock | $12.98B | $13.07B | $13.16B | $11.75B | $11.74B | $11.73B | $11.81B | $11.78B | $11.81B | $11.78B | $11.70B | $11.81B | $11.83B | $10.81B | $10.84B | $10.11B | $10.05B | $3.33B | $3.33B | $3.03B |
| Retained Earnings | $-7.31B | $-7.12B | $-7.06B | $-6.74B | $-6.65B | $-5.78B | $-5.78B | $-5.63B | $-5.78B | $-5.63B | $-1.52B | $-1.55B | $-1.60B | $-1.32B | $-1.32B | $-1.24B | $-958.87M | $-965.28M | $-928.05M | $-926.56M |
| Accumulated Other Comprehensive Income Loss | $-526.30M | $-433.80M | $-497.00M | $-512.30M | $-495.30M | $-657.80M | $-487.60M | $-577.50M | $-487.60M | $-577.50M | $-519.20M | $103.50M | $326.75M | $324.90M | $571.55M | $523.36M | $503.52M | $-5.19M | $-15.63M | $-13.35M |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-11.30M | $-15.60M | $-48.70M | $-16.96M | $- | $- | $- | $363.14M | $- | $- | $- |
| Total Stockholders Equity | $5.14B | $5.51B | $5.60B | $5.89B | $5.99B | $6.68B | $6.94B | $6.96B | $6.94B | $6.96B | $11.04B | $11.71B | $11.93B | $11.21B | $11.49B | $9.40B | $9.59B | $2.36B | $2.38B | $2.09B |
| Total Equity | $5.14B | $5.51B | $5.60B | $5.89B | $5.99B | $6.68B | $6.94B | $6.96B | $6.94B | $6.96B | $11.04B | $11.71B | $11.93B | $11.21B | $11.49B | $9.40B | $9.59B | $2.36B | $2.38B | $2.09B |
| Total Liabilities and Stockholders Equity | $11.49B | $12.03B | $12.08B | $12.50B | $12.71B | $13.42B | $13.71B | $13.94B | $13.71B | $13.94B | $18.84B | $19.74B | $20.18B | $18.50B | $19.15B | $15.11B | $15.20B | $5.15B | $5.21B | $5.00B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $11.49B | $12.03B | $12.08B | $12.50B | $12.71B | $13.42B | $13.71B | $13.94B | $13.71B | $13.94B | $18.84B | $19.74B | $20.18B | $18.50B | $19.15B | $15.11B | $15.20B | $5.15B | $5.21B | $5.00B |
| Total Investments | $- | $7.40M | $26.00M | $25.70M | $17.70M | $2.50M | $31.00M | $18.50M | $47.20M | $50.40M | $- | $- | $1.96M | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $4.59B | $4.71B | $4.73B | $4.72B | $4.81B | $4.96B | $4.95B | $4.98B | $4.95B | $4.98B | $5.59B | $5.60B | $5.61B | $5.40B | $5.57B | $3.60B | $3.63B | $2.03B | $2.03B | $2.03B |
| Net Debt | $4.30B | $4.32B | $4.35B | $4.36B | $4.44B | $4.56B | $4.52B | $4.62B | $4.52B | $4.62B | $5.23B | $5.10B | $5.18B | $2.92B | $3.01B | $3.20B | $3.37B | $1.43B | $1.42B | $1.73B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-636.70M | $-911.20M | $-3.96B | $-3.96B | $-270.45M |
| Depreciation and Amortization | $727.00M | $708.30M | $710.50M | $710.50M | $537.82M |
| Deferred Income Tax | $21.20M | $-78.40M | $-54.30M | $-54.30M | $-13.36M |
| Stock Based Compensation | $59.90M | $109.00M | $93.90M | $33.30M | $34.20M |
| Change in Working Capital | $-24.90M | $-60.40M | $-271.90M | $-271.90M | $68.08M |
| Accounts Receivables | $92.60M | $-25.50M | $-28.30M | $-28.30M | $-64.07M |
| Inventory | $- | $- | $-210.30M | $- | $100.75M |
| Accounts Payables | $-15.00M | $41.20M | $-24.00M | $-24.00M | $31.19M |
| Other Working Capital | $-102.50M | $-76.10M | $-9.30M | $-219.60M | $207.00K |
| Other Non Cash Items | $500.10M | $976.90M | $3.99B | $3.99B | $-31.65M |
| Net Cash Provided by Operating Activities | $646.60M | $744.20M | $509.30M | $509.30M | $323.77M |
| Investments in Property Plant and Equipment | $-289.10M | $-242.50M | $-202.90M | $-202.90M | $-118.54M |
| Acquisitions Net | $-32.00M | $5.10M | $260.20M | $260.20M | $-3.93B |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $84.40M | $- | $285.00M | $4.30M | $41.40M |
| Net Cash Used for Investing Activities | $-236.70M | $-237.40M | $57.30M | $57.30M | $-4.04B |
| Debt Repayment | $-198.10M | $-301.00M | $-498.40M | $1.99B | $1.88B |
| Common Stock Issued | $- | $- | $5.70M | $- | $843.70M |
| Common Stock Repurchased | $-200.00M | $-100.00M | $-175.00M | $- | $- |
| Dividends Paid | $-37.70M | $-75.50M | $-75.40M | $-18.87M | $- |
| Other Financing Activities | $-34.30M | $-20.00M | $-16.10M | $3.64B | $200.50M |
| Net Cash Used Provided by Financing Activities | $-470.10M | $-496.50M | $-759.20M | $-759.20M | $4.03B |
| Effect of Forex Changes on Cash | $-15.30M | $3.60M | $-38.20M | $-38.20M | $3.74M |
| Net Change in Cash | $-75.50M | $13.90M | $-230.80M | $-230.80M | $315.20M |
| Cash at End of Period | $295.20M | $370.70M | $356.80M | $356.80M | $587.61M |
| Cash at Beginning of Period | $370.70M | $356.80M | $587.60M | $587.60M | $272.41M |
| Operating Cash Flow | $646.60M | $744.20M | $509.30M | $509.30M | $323.77M |
| Capital Expenditure | $-289.10M | $-242.50M | $-202.90M | $-202.90M | $-118.54M |
| Free Cash Flow | $357.50M | $501.70M | $306.40M | $306.40M | $205.22M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-191.80M | $-65.60M | $-304.30M | $-75.00M | $-843.90M | $12.30M | $-123.10M | $43.50M | $-123.10M | $43.50M | $62.40M | $69.50M | $-187.60M | $23.31M | $-82.21M | $-23.95M | $6.42M | $-37.23M | $-1.49M | $-74.00M |
| Depreciation and Amortization | $186.00M | $177.20M | $184.40M | $179.40M | $180.80M | $176.80M | $178.10M | $172.60M | $178.10M | $172.60M | $175.60M | $176.40M | $145.30M | $130.68M | $130.18M | $131.65M | $126.95M | $68.61M | $56.15M | $51.44M |
| Deferred Income Tax | $50.00M | $-4.20M | $-24.60M | $- | $-27.10M | $-3.50M | $-50.70M | $1.10M | $-50.70M | $-2.40M | $400.00K | $-1.30M | $-2.27M | $-10.49M | $-751.00K | $162.00K | $-37.69M | $-779.00K | $-10.86M | $4.21M |
| Stock Based Compensation | $11.00M | $15.00M | $18.90M | $14.90M | $11.90M | $25.50M | $30.90M | $40.70M | $27.40M | $19.30M | $22.60M | $24.60M | $-3.62M | $13.65M | $12.82M | $10.48M | $9.08M | $5.52M | $4.32M | $16.50M |
| Change in Working Capital | $-52.30M | $14.90M | $-57.00M | $42.10M | $-2.90M | $-37.10M | $-25.70M | $5.30M | $-25.70M | $5.30M | $-97.90M | $-91.30M | $34.08M | $-24.47M | $-26.63M | $85.10M | $54.45M | $-49.83M | $8.66M | $53.96M |
| Accounts Receivables | $-55.60M | $45.00M | $28.40M | $74.80M | $-135.80M | $-11.40M | $79.40M | $42.30M | $79.40M | $42.30M | $13.60M | $40.20M | $-178.10M | $5.36M | $64.46M | $44.22M | $-113.16M | $36.36M | $63.76M | $29.28M |
| Inventory | $- | $- | $- | $- | $108.50M | $21.40M | $-7.50M | $-122.40M | $-7.50M | $- | $- | $- | $78.02M | $40.60M | $20.98M | $-38.86M | $-12.54M | $4.21M | $-1.69M | $-16.81M |
| Accounts Payables | $1.50M | $-4.30M | $25.10M | $-37.30M | $43.60M | $-8.60M | $6.30M | $-100.00K | $6.30M | $-100.00K | $1.50M | $-10.30M | $17.64M | $7.62M | $-7.82M | $13.75M | $5.54M | $-2.54M | $-6.61M | $758.00K |
| Other Working Capital | $1.80M | $-25.80M | $-110.50M | $31.00M | $89.30M | $-38.50M | $-103.90M | $85.50M | $-103.90M | $-36.90M | $-92.80M | $-121.20M | $116.52M | $-78.05M | $-104.25M | $65.99M | $174.61M | $-87.85M | $-46.80M | $40.73M |
| Other Non Cash Items | $138.40M | $65.60M | $642.80M | $14.80M | $872.10M | $-10.60M | $152.90M | $-35.70M | $152.90M | $-32.20M | $-15.60M | $-110.50M | $32.35M | $-88.83M | $54.23M | $-29.40M | $-23.73M | $34.16M | $4.67M | $-6.01M |
| Net Cash Provided by Operating Activities | $141.30M | $202.90M | $126.00M | $176.20M | $190.90M | $163.40M | $162.40M | $227.50M | $162.40M | $227.50M | $97.20M | $67.40M | $18.25M | $43.85M | $87.63M | $174.04M | $135.48M | $20.46M | $61.46M | $46.11M |
| Investments in Property Plant and Equipment | $-82.20M | $-76.60M | $-65.90M | $-64.40M | $-63.90M | $-61.70M | $-57.60M | $-59.30M | $-57.60M | $-59.30M | $-47.70M | $-41.40M | $-32.35M | $-24.18M | $-29.05M | $-32.97M | $-29.12M | $-25.95M | $-39.24M | $-19.39M |
| Acquisitions Net | $103.60M | $4.30M | $-36.30M | $- | $-3.10M | $-1.20M | $10.50M | $-1.10M | $10.50M | $-1.10M | $-13.00M | $-1.30M | $-3.91B | $-14.75M | $- | $433.00K | $-2.00B | $- | $- | $-881.57M |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $5.00M | $- | $-5.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-279.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-19.20M | $-19.20M | $- | $10.50M | $- | $10.50M | $- | $274.50M | $- | $- | $- | $4.30M | $- | $- | $- | $37.65M | $- | $-5.98M | $3.75M |
| Net Cash Used for Investing Activities | $21.40M | $-91.50M | $-102.20M | $-64.40M | $-67.00M | $-62.90M | $-47.10M | $-60.40M | $-47.10M | $-60.40M | $-60.70M | $-42.70M | $-3.94B | $-38.92M | $-29.05M | $-32.54M | $-2.03B | $-25.95M | $-39.24M | $-900.97M |
| Debt Repayment | $-139.30M | $-5.70M | $-5.40M | $-47.70M | $-150.20M | $-300.00K | $-25.30M | $-125.20M | $-475.40M | $-7.70M | $-7.60M | $-7.70M | $167.69M | $-164.60M | $1.99B | $-7.20M | $1.60B | $-3.15M | $-3.15M | $291.85M |
| Common Stock Issued | $- | $- | $- | $- | $-9.70M | $- | $2.20M | $7.50M | $3.50M | $1.30M | $1.00M | $- | $139.82M | $-700.00K | $728.77M | $5.07M | $-8.00K | $111.00K | $303.17M | $540.60M |
| Common Stock Repurchased | $-100.00M | $-100.00M | $-1.30M | $-8.60M | $- | $-100.00M | $-2.20M | $-7.50M | $- | $- | $-119.90M | $-55.10M | $-94.14M | $-65.22M | $- | $-4.50M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $-18.80M | $-18.90M | $-18.80M | $-19.00M | $-18.80M | $-18.90M | $-18.80M | $-18.90M | $-18.80M | $-18.90M | $-18.87M | $-1.00K | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-300.00K | $-4.00M | $-1.40M | $-28.60M | $-5.30M | $-5.10M | $-2.10M | $-7.50M | $-1.00M | $-2.80M | $-5.20M | $-7.10M | $-27.33M | $-916.00K | $2.79B | $635.00K | $-40.34M | $-2.89M | $-15.37M | $259.16M |
| Net Cash Used Provided by Financing Activities | $-239.60M | $-109.70M | $-25.40M | $-95.20M | $-174.30M | $-124.40M | $-46.20M | $-151.60M | $-46.20M | $-151.60M | $-150.60M | $-88.80M | $167.18M | $-231.42M | $4.10B | $-6.57M | $1.56B | $-6.17M | $284.65M | $1.09B |
| Effect of Forex Changes on Cash | $-16.40M | $10.40M | $-3.00M | $-6.30M | $13.90M | $-12.00M | $-300.00K | $2.00M | $-300.00K | $2.00M | $-28.70M | $-7.80M | $8.60M | $-9.88M | $-3.55M | $8.58M | $1.40M | $2.77M | $-7.21M | $-2.01M |
| Net Change in Cash | $-93.30M | $12.10M | $14.60M | $10.30M | $-36.50M | $-35.90M | $68.80M | $17.50M | $68.80M | $17.50M | $-142.80M | $-71.90M | $-3.75B | $-236.38M | $4.16B | $143.51M | $-332.63M | $-8.89M | $299.66M | $234.73M |
| Cash at End of Period | $295.20M | $388.50M | $376.40M | $381.00M | $370.70M | $407.20M | $443.10M | $374.30M | $443.10M | $374.30M | $372.90M | $515.70M | $587.61M | $4.33B | $4.57B | $412.52M | $269.01M | $601.64M | $610.53M | $310.87M |
| Cash at Beginning of Period | $388.50M | $376.40M | $361.80M | $370.70M | $407.20M | $443.10M | $374.30M | $356.80M | $374.30M | $356.80M | $515.70M | $587.60M | $4.33B | $4.57B | $412.52M | $269.01M | $601.64M | $610.53M | $310.87M | $76.14M |
| Operating Cash Flow | $141.30M | $202.90M | $126.00M | $176.20M | $190.90M | $163.40M | $162.40M | $227.50M | $162.40M | $227.50M | $97.20M | $67.40M | $18.25M | $43.85M | $87.63M | $174.04M | $135.48M | $20.46M | $61.46M | $46.11M |
| Capital Expenditure | $-82.20M | $-76.60M | $-65.90M | $-64.40M | $-63.90M | $-61.70M | $-57.60M | $-59.30M | $-57.60M | $-59.30M | $-47.70M | $-41.40M | $-32.35M | $-24.18M | $-29.05M | $-32.97M | $-29.12M | $-25.95M | $-39.24M | $-19.39M |
| Free Cash Flow | $59.10M | $126.30M | $60.10M | $111.80M | $127.00M | $101.70M | $104.80M | $168.20M | $104.80M | $168.20M | $49.50M | $26.00M | $-14.09M | $19.67M | $58.58M | $141.06M | $106.36M | $-5.49M | $22.22M | $26.71M |
Clarivate Plc Dividends
Explore Clarivate Plc's dividend history, including dividend yield, payout ratio, and historical payments.
Clarivate Plc News
Read the latest news about Clarivate Plc, including recent articles, headlines, and updates.
Clarivate Partners with Iprova to Streamline the Invention Creation and Submission Process
The partnership will see Iprova's suite of solutions integrated with IP management software IPfolio LONDON , March 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with Iprova, the world's first data-driven invention company and developer of state-of-the-art Artificial Intelligence-based technologies which augment and enhance the human ability to invent. This partnership will combine Iprova's product suite for collaboratively capturing, creating and refining inventive concepts with IPfolio, the industry-leading IP management software, enabling a smooth transition of inventions into the patent workflow.
TE Connectivity ranks among Clarivate Top 100 Global Innovators 2025
List highlights organizations at the forefront of technology research and innovation GALWAY, Ireland , March 12, 2025 /PRNewswire/ -- TE Connectivity, a world leader in connectors and sensors, has been named among the Clarivate Top 100 Global Innovators, an annual list of organizations that prioritize innovation as a business strategy. Innovation is a core value at TE, which has been named a Top 100 Global Innovator 12 times since Clarivate created the recognition in 2012.
Philips highest ranked medical technology company among Clarivate Top 100 Global Innovators
March 12, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has been recognized by Clarivate as the top-ranked medical technology company in the Top 100 Global Innovators 2025, reinforcing its global reputation as a leading healthcare innovator. A consistent high-performer, Philips has been included in this major assessment of global innovators for 12 consecutive years. Roy Jakobs, CEO of Royal Philips said: "At Philips, we've been innovating for over 130 years to improve people's lives. Innovation is our fundamental strength, the reason why customers choose us as their strategic partner and a key value driver for our company. Our portfolio of patient- and people-centric innovations in hardware, software, AI and services drives healthcare productivity and empowers people to look after their health and well-being – delivering better care for more people." In 2024, Philips invested approximately EUR 1.7 billion – or an industry leading >9% of sales – in research and development to help drive better care for more people. Philips is increasingly focusing its innovation efforts on the potential of data and AI, both in hospital settings and at home. As a leader in AI-related patent applications in healthcare, Philips dedicates around half of its R&D workforce to these fields. Examples of Philips' AI-powered innovations that increase caregiver productivity and deliver better care for more people include:
Clarivate Reveals Top 100 Global Innovators 2025
The Top 100 organizations generate $4.6 trillion USD in annual revenues, representing 4.4% of the global economy LONDON , March 12, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2025 ranked list of Top 100 Global Innovators – the organizations at the forefront of technology research and innovation worldwide. The Top 100 organizations prioritize innovation as a central part of their business strategy.
Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON , Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing? , shedding light on the pharmaceutical industry's evolution in the region.
Clarivate Plc (CLVT) Q4 2024 Earnings Call Transcript
Clarivate Plc (NYSE:CLVT ) Q4 2024 Earnings Conference Call February 19, 2025 9:00 AM ET Company Participants Mark Donohue - VP of IR Matti Shem Tov - CEO Jonathan Collins - CFO Conference Call Participants Manav Patnaik - Barclays Andrew Nicholas - William Blair George Tong - Goldman Sachs Owen Lau - Oppenheimer Shlomo Rosenbaum - Stifel Surinder Thind - Jefferies Peter Christiansen - Citi Ashish Sabadra - RBC Capital Markets Operator Thank you for standing by. My name is Kate, and I will be your conference operator today.
Compared to Estimates, Clarivate (CLVT) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Clarivate (CLVT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Clarivate Reports Fourth Quarter and Full Year 2024 Results
— Accelerates transition from transactional to subscription and re-occurring revenue — — Launches new product innovation for Academia & Government and Life Sciences & Healthcare — — Repurchased $200 million ordinary shares and pre-paid $198 million of debt in 2024 as part of balanced capital allocation strategy — — Initiates review of strategic alternatives including potential divestitures — — Provides 2025 Outlook — LONDON , Feb. 19, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the fourth quarter and full year ended December 31, 2024. Total revenue for the fourth quarter of 2024 was $663.0 million, compared to total revenue of $683.7 million in the fourth quarter of 2023.
Clarivate Unveils Transformative Subscription-Based Access Strategy for Academia
New approach enables broad, simple and affordable access to trusted scholarly content for learning and research LONDON , Feb. 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a new subscription-based content access strategy. The new approach breaks down barriers through broad and affordable access to highly curated, trusted academic resources, including Ebooks and primary digital collections, enabling every library to support research, teaching and learning goals.
Exploring Analyst Estimates for Clarivate (CLVT) Q4 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Clarivate (CLVT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Clarivate Recognized for Excellence in Trademark Business in the WTR 1000 2025
Highly recommended in trademark management, searching and watching, renewals and recordals LONDON , Feb. 10, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has been recognized by the World Trademark Review for three categories in the WTR 1000 2025 . This guide identifies the top trademark professionals and firms in key jurisdictions around the globe.
Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform
Software-as-a-Service, cloud-based library services and discovery platform to be implemented in nine universities and 82 academic and research libraries across Croatia LONDON , Feb. 5, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that the National and University Library in Zagreb has selected Clarivate to provide its unified library services and discovery platform. The National and University Library in Zagreb (NSK) is Croatia's leading cultural and research institution, serving as both the National Library of Croatia and the University of Zagreb's main library.
Clarivate Reveals Medtech Breakthroughs Driving Growth in Pulsed Field Ablation Market
New e-book explores transformative medtech advancements in pulsed field ablation for atrial fibrillation treatment LONDON , Feb. 4, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence and BioWorld by Clarivate, today published a new e-book, Pulsed field ablation: stunning growth shocks the atrial fibrillation market . The Clarivate e-book highlights new medtech breakthroughs in the pulsed field ablation (PFA) market, forecasting its future growth and showcasing the technology's potential to transform the treatment paradigm for atrial fibrillation.
Clarivate identifies top 50 universities powering global innovation
Report from the Institute for Scientific Information shows how academic research drives global innovation and benefits society LONDON , Jan. 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released The top 50 universities powering global innovation report which analyzes the critical role of research in shaping global industrial innovation and societal impact, using data and expert insights derived from academic research and patent citations. Drawing on a host of Clarivate data - from the Web of Science to Derwent World Patents Index, and Derwent Patents Citation Index – the report highlights how knowledge flows between academia and industry across countries and regions, underscoring the global nature of innovation.
The British Library Selects Clarivate to Provide Library Services and Discovery Platforms
Achieving more unified and secure workflows with cloud-based Alma, Primo and Rapido library software solutions from Clarivate LONDON , Jan. 28, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces that the British Library has selected Clarivate to provide its library services and discovery platforms to create a more cohesive, streamlined and secure experience. The British Library will implement Alma, Primo VE and Rapido.
Clarivate to Report Fourth Quarter and Full Year 2024 Results on February 19, 2025
LONDON , Jan. 22, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the fourth quarter and full year 2024 before the market opens on Wednesday, February 19, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.
Does Clarivate (CLVT) Have the Potential to Rally 29.13% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Clarivate (CLVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON , Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025.
Post-marketing Pharmacovigilance and Medical Information Market Research 2024: Rising Adverse Drug Reactions (ADRs) and Expanding Use of Biologics and Specialty Drugs Fueling Growth - Forecast to 2034
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Post-marketing Pharmacovigilance and Medical Information Market by Type by Service, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global post-marketing pharmacovigilance and medical information market size was estimated to be USD 6.22 billion in 2023 and is expected to reach USD 16.99 billion by 2034 with a CAGR of 9.56% during the forecast period 2024-2034.
Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON , Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes — eliminating the complexities of raw data management.
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON , Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
Clarivate Announces New $500 Million Share Repurchase Authorization
LONDON , Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which terminates December 31, 2024, under which the Company repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024.
Clarivate Launches AI-Powered Patent Search Solution in Derwent
Faster and more relevant results to empower critical IP decision-making LONDON , Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in less time.
Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts
Revealing highly active specialties in sciences and social sciences LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.
Daikin Selects IPfolio from Clarivate
Enhancing operational efficiency for leading air conditioner manufacturer LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Daikin Industries, Ltd. (Daikin) has selected IPfolio™ from Clarivate.
BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series
New seven-part series explores disparities in care, funding and innovation impacting half the world's population LONDON , Nov. 21, 2024 /PRNewswire/ -- BioWorld ™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide. ' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment.
Clarivate Reveals Highly Cited Researchers 2024 List
Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON , Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,636 Highly Cited Researchers in 2024 from more than 1,200 institutions in 59 nations and regions.
New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON , Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come . Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches.
Similar Companies
Science Applications International Corporation
SAIC
Price: $105.90
Market Cap: $5.06B
Related Metrics
Explore detailed financial metrics and analysis for CLVT.